- Oops!Something went wrong.Please try again later.
Announced that its wholly-owned subsidiary, PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the intellectual property of ketamine in the treatment amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease. The University of Kansas Medical Center inventors Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery that ketamine can be administered as an effective treatment for ALS. Their preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and increases life expectancy when given in the early stages of muscle decline. Currently, there is no known cure for ALS. Peak sales for a new drug to treat ALS can achieve over USD $1 billion. Newscope Capital Corporation shares C.PHRM are trading up 2 cents at $0.34.